US 11,939,608 B2
Engineered heme-binding compositions and uses thereof
Michael Super, Lexington, MA (US); Alexander L. Watters, North Andover, MA (US); Philip T. Snell, Lexington, MA (US); and Donald E. Ingber, Boston, MA (US)
Assigned to PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Filed by PRESIDENT AND FELLOWS OF HARVARD COLLEGE, Cambridge, MA (US)
Filed on Mar. 18, 2022, as Appl. No. 17/698,576.
Application 17/698,576 is a continuation of application No. 16/661,595, filed on Oct. 23, 2019, granted, now 11,312,949.
Application 16/661,595 is a continuation of application No. 15/968,116, filed on May 1, 2018, granted, now 10,501,729, issued on Dec. 10, 2019.
Application 15/968,116 is a continuation of application No. 14/892,252, granted, now 9,988,617, issued on Jun. 5, 2018, previously published as PCT/US2014/038945, filed on May 21, 2014.
Claims priority of provisional application 61/825,707, filed on May 21, 2013.
Prior Publication US 2022/0267749 A1, Aug. 25, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/26 (2006.01); A61K 38/00 (2006.01); C07K 14/805 (2006.01); C12N 9/96 (2006.01)
CPC C12N 9/2474 (2013.01) [A61K 38/00 (2013.01); C07K 14/805 (2013.01); C12N 9/96 (2013.01); C12Y 302/01035 (2013.01)] 13 Claims
 
1. An engineered heme-binding molecule comprising a heme-binding domain and an Fc domain; wherein the heme-binding domain is conjugated to the Fc domain; and wherein the heme-binding domain comprises a polypeptide that is at least 90% identical to a sequence corresponding to residues 24-462 of SEQ ID NO: 1.